Perceptive Advisors LLC holds a focused book of 92 stocks worth $5.1B as of Q1 2026 (disclosed May 29, 2026, a ~59-day 13F lag). This quarter they opened Ionis Pharmaceuticals Inc and trimmed Celcuity Inc. Their largest long position is Praxis Precision Medicines I at 13% of the equity book. They also disclosed $50.8M in put options (a bearish bet) and $4.2M in call options (bullish), shown separately below and excluded from the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
91% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Perceptive Advisors LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 79 / 80 | $7.6B |
| UBS Group AG | 78 / 80 | $4.6B |
| GOLDMAN SACHS GROUP INC | 76 / 80 | $4.4B |
| BANK OF AMERICA CORP /DE/ | 75 / 80 | $3.8B |
| BARCLAYS PLC | 75 / 80 | $1.0B |
| BNP PARIBAS FINANCIAL MARKETS | 75 / 80 | $865.8M |
| CITIGROUP INC | 75 / 80 | $595.1M |
| BlackRock, Inc. | 74 / 80 | $31.5B |
Ranked by how many of Perceptive Advisors LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I COM NEW | $656.0M | 2.04M | 13.0% | ▲+2.0% Added · +40K sh | |
| 2 | Celcuity Inc COM | $356.9M | 3.13M | 7.1% | ▼−1.0% Reduced · −33K sh | |
| 3 | Ascendis Pharma A/s SPONSORED ADR | $350.3M | 1.53M | 6.9% | ▲+42% Added · +450K sh | |
| 4 | Roivant Sciences Ltd SHS | $229.5M | 8.29M | 4.5% | ▲+3.8% Added · +300K sh | |
| 5 | Centessa Pharmaceuticals PLC SPONSORED ADS | $208.9M | 5.26M | 4.1% | ▲+80% Added · +2.3M sh | |
| 6 | Rhythm Pharmaceuticals Inc COM | $206.4M | 2.37M | 4.1% | ▼−6.8% Reduced · −173K sh | |
| 7 | Spyre Therapeutics Inc COM NEW | $190.8M | 3.78M | 3.8% | ▲+23% Added · +714K sh | |
| 8 | Nuvalent Inc COM | $161.9M | 1.58M | 3.2% | ▼−5.1% Reduced · −85K sh | |
| 9 | Edgewise Therapeutics Inc COM | $139.4M | 4.42M | 2.8% | ▼−0.8% Reduced · −34K sh | |
| 10 | Protagonist Therapeutics Inc COM | $129.7M | 1.23M | 2.6% | ▼−8.8% Reduced · −120K sh | |
| 11 | Apogee Therapeutics Inc COM | $129.7M | 1.54M | 2.6% | ▼−34% Reduced · −790K sh | |
| 12 | Travere Therapeutics Inc COM | $123.1M | 4.14M | 2.4% | ▼−3.2% Reduced · −136K sh | |
| 13 | Amylyx Pharmaceuticals Inc COM | $115.2M | 8.28M | 2.3% | —Held | |
| 14 | Immatics N.V SHS | $102.2M | 10.38M | 2.0% | —Held | |
| 15 | Relay Therapeutics Inc COM | $97.0M | 9.75M | 1.9% | ▲+412% Added · +7.8M sh | |
| 16 | Inhibrx Biosciences Inc COM | $97.0M | 1.44M | 1.9% | ▼−0.7% Reduced · −10K sh | |
| 17 | Meiragtx Hldgs PLC COM | $89.3M | 10.33M | 1.8% | —Held | |
| 18 | Zymeworks Inc COM | $87.9M | 3.51M | 1.7% | ▲+7.6% Added · +248K sh | |
| 19 | Solid Biosciences Inc COM NEW | $85.7M | 11.91M | 1.7% | ▲+0.6% Added · +73K sh | |
| 20 | Dyne Therapeutics Inc COM | $84.6M | 4.67M | 1.7% | ▲+34% Added · +1.2M sh | |
| 21 | Biocryst Pharmaceuticals Inc COM | $70.8M | 7.43M | 1.4% | ▲+135% Added · +4.3M sh | |
| 22 | Oruka Therapeutics Inc COM | $68.4M | 1.40M | 1.4% | ▼−5.5% Reduced · −81K sh | |
| 23 | Artivion Inc COM | $60.0M | 1.64M | 1.2% | ▼−4.9% Reduced · −85K sh | |
| 24 | Nurix Therapeutics Inc COM | $57.5M | 3.71M | 1.1% | ▲+4.3% Added · +155K sh | |
| 25 | Nautilus Biotechnology Inc COM | $48.9M | 12.59M | 1.0% | —Held | |
| 26 | Cytomx Therapeutics Inc. COM | $47.5M | 10.10M | 0.9% | ▲+4.3% Added · +419K sh | |
| 27 | Alto Neuroscience Inc COM SHS | $45.2M | 2.01M | 0.9% | ▲+13% Added · +226K sh | |
| 28 | Engene Holdings Inc COM | $39.7M | 5.83M | 0.8% | ▼−0.7% Reduced · −42K sh | |
| 29 | Immunovant Inc COM | $39.7M | 1.60M | 0.8% | ▼−20% Reduced · −398K sh | |
| 30 | Intuitive Surgical Inc COM NEW | $39.4M | 85.4K | 0.8% | ▼−2.8% Reduced · −3K sh | |
| 31 | Ionis Pharmaceuticals Inc COM | $37.8M | 504.0K | 0.7% | ▲New New position | |
| 32 | Day One Biopharmaceuticals I COM | $37.6M | 1.76M | 0.7% | ▲New New position | |
| 33 | Abivax Sa SPONSORED ADS | $36.6M | 328.9K | 0.7% | ▼−28% Reduced · −129K sh | |
| 34 | Corvus Pharmaceuticals Inc COM | $33.5M | 2.29M | 0.7% | ▲+231% Added · +1.6M sh | |
| 35 | Repligen Corp COM | $33.1M | 280.5K | 0.7% | ▼−11% Reduced · −35K sh | |
| 36 | Jazz Pharmaceuticals PLC SHS USD | $32.1M | 170.0K | 0.6% | —Held | |
| 37 | Damora Therapeutics Inc COM NEW | $31.7M | 1.22M | 0.6% | ▲New New position | |
| 38 | X4 Pharmaceuticals Inc COM NEW | $27.8M | 6.74M | 0.5% | ▲+6.7% Added · +423K sh | |
| 39 | Guardant Health Inc COM | $27.7M | 300.0K | 0.5% | ▲+88% Added · +140K sh | |
| 40 | Bright Minds Biosciences Inc COM NEW | $27.5M | 377.5K | 0.5% | ▼−16% Reduced · −72K sh | |
| 41 | Invivyd Inc COM | $27.1M | 20.86M | 0.5% | ▼−4.2% Reduced · −926K sh | |
| 42 | Sionna Therapeutics Inc COM | $26.4M | 658.4K | 0.5% | ▼−44% Reduced · −521K sh | |
| 43 | Axsome Therapeutics Inc. COM | $25.3M | 149.9K | 0.5% | ▲+0.7% Added · +1K sh | |
| 44 | Revolution Medicines Inc COM | $25.1M | 258.6K | 0.5% | ▲New New position | |
| 45 | SAB Biotherapeutics Inc COM NEW | $24.6M | 6.43M | 0.5% | ▲+701% Added · +5.6M sh | |
| 46 | Belite Bio Inc SPONSORED ADS | $24.2M | 152.0K | 0.5% | ▼−63% Reduced · −262K sh | |
| 47 | Tenax Therapeutics Inc COM NEW | $23.2M | 1.45M | 0.5% | ▲+230% Added · +1.0M sh | |
| 48 | Axogen Inc COM | $23.1M | 697.3K | 0.5% | ▼−11% Reduced · −87K sh | |
| 49 | Viridian Therapeutics Inc COM | $22.9M | 1.17M | 0.5% | ▼−62% Reduced · −1.9M sh | |
| 50 | Orchestra Biomed Hldgs Inc COM | $21.4M | 5.04M | 0.4% | ▼−1.7% Reduced · −89K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1224962/holdings"
Use Arkolith to show PERCEPTIVE ADVISORS LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | MODERNA INCMRNA | $50.8M | 1.0M |
| CALL · bullish | OCULAR THERAPEUTIX INCOCUL | $4.2M | 500K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 29, 2026 | 94 | $5.1B | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 116 | $5.6B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 93 | $3.5B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 85 | $2.7B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | Aug 6, 2025 | 87 | $2.8B | 13F-HR/A |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 99 | $3.6B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 108 | $4.7B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 16, 2024 | 110 | $4.2B | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | Aug 6, 2024 | 112 | $5.7B | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 26, 2024 | 101 | $4.5B | 13F-HR/A |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 97 | $3.0B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 24, 2023 | 95 | $3.5B | 13F-HR/A |
| Q1 2023 | Mar 31, 2023 | May 16, 2023 | 99 | $3.4B | 13F-HR/A |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 96 | $3.6B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 116 | $3.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 111 | $3.2B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 135 | $5.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.